En Es
Categories

Industry News

Seegene Develops World’s First Multiplex MDx Assays with AI System

By Labmedica International staff writers
09 Jan 2018

Image: Seegene has developed the world’s first molecular diagnostics assays using an artificial intelligence-based automated assay development system (Photo courtesy of Seegene).Seegene Inc. (Seoul, South Korea), a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.

The Seegene Digitalized Development System (SG-DDS) automates real-time PCR assay development by utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This significantly reduces the time and labor required for R&D and simplifies the complicated real time PCR assay development processes, thereby allowing even non-professionals to easily develop multiplex MDx assays according to their requirement.

"The performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed," said a spokesperson from Seegene. "Only four days were sufficient by the AI system to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals."

"We have already witnessed AI surpassing human intelligence in developing medical devices. Therefore, all molecular diagnostic assays will be developed by AI instead of professional researchers," added Dr. Jong-Yoon Chun, CEO and Founder of Seegene. "SG-DDS is now the most economical solution to MDx assay development as it saves time and labor, and will ultimately drive down the cost of molecular diagnostic tests, one of the biggest obstacles in MDx market. SG-DDS will lead to standardization of MDx system and promote tailor-made medical treatment."



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
More info

More articles about Seegene

19 Apr 2018
Seegene Unveils Combination Test at ECCMID 2018
Seegene Inc., a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.
Read More
28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More
29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More

Additional news

15 Oct 2018
AI Algorithm Uses Key Signatures to Predict Onset of AD
A team of researchers has designed an artificial intelligence (AI) algorithm that learns signatures from magnetic resonance imaging (MRI), genetics, and clinical data to accurately predict cognitive decline leading to Alzheimer’s disease. The algorithm can help predict whether an individual’s cognitive faculties are likely to deteriorate towards Alzheimer’s in the next five years.
Read More
15 Oct 2018
Breast Cancer Screening Machine Learning Software Receives CE Mark
A new deep learning-based breast cancer screening software has received the CE mark and will be launched within the UK’s National Health Service (NHS) and European healthcare systems. The software has been developed by Kheiron Medical Technologies, a start-up that combines novel deep learning methods, data science, and radiology expertise to enable diagnostics designed to detect cancers and improve patient outcomes.
Read More
15 Oct 2018
GE Healthcare to Implement First AI-Powered Hospital Command Centers
GE Healthcare is collaborating with hospital service providers in Europe and the US for implementing an artificial intelligence (AI)-powered command center to effectively and efficiently synchronize all elements of a patient's hospital experience. The AI-powered system will support caregivers to enhance patient safety, orchestrate seamless care delivery and get patients back home sooner.
Read More
11 Oct 2018
Scientists Use Machine Learning and MRI Scans to Predict Learning Difficulties
A team of scientists from the Medical Research Council (MRC) Cognition and Brain Sciences Unit at the University of Cambridge used machine learning - a type of artificial intelligence - with data from hundreds of children who struggle at school to identify clusters of learning difficulties, which did not match their previous diagnosis. According to the researchers, this reinforces the need for children to receive detailed assessments of their cognitive skills to identify the best type of support.
Read More
10 Oct 2018
Utilization of X-Ray Mammography Systems Expected to Increase
Over the last 20 years, hospitals and imaging centers in the developed economies have adopted X-ray mammography systems for the screening and diagnosis of breast cancer. This has resulted in a significant reduction in mortality and encouraged emerging countries to make investments in population-base, organized screening. These significant investments in mammography technology have paved the way for radiation safety, patient comfort and 3D imaging that enables precise tumor detection.
Read More
09 Oct 2018
Compact Devices Emerge As Segment of Ultrasound Market
The global ultrasound devices market was valued at USD 6.5 billion in 2017 and is projected to grow at a CAGR of 5.6% from 2018 to 2026 to reach USD 10.6 billion by 2026, as a surge in the incidence of disorders such as cardiovascular diseases, respiratory and abdominal disorders is likely to boost the demand for ultrasound devices.
Read More
02 Oct 2018
AI and fMRI Show How Brain Connects Memories to Solve Problems
A team of German neuroscientists and Artificial Intelligence (AI) researchers have published results from their study that provided insights into the way the human brain connects individual episodic memories, or memories of specific events, to solve problems.
Read More
02 Oct 2018
Medical Robots Market to Reach USD 28 Billion in 2025
The global medical robots market is estimated to grow with a CAGR of 22.3% from USD 5.74 billion in 2017 to USD 28.78 billion in 2025, driven by increasing training programs for robotic surgeries and a rise in the usage of robots across various healthcare fields such as surgeries, therapies, rehabilitation, pharmacy dispensing, sanitation and others. These are the latest findings of Research and Markets, a global market research company.
Read More
01 Oct 2018
AI Tool Identifies Cancer Type and Changes in Lung Tumor
Researchers from the NYU School of Medicine have developed a new computer program that can analyze the images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth. In their study, the researchers found that the artificial intelligence (AI), or "machine learning," program could distinguish -- with 97% accuracy -- between adenocarcinoma and squamous cell carcinoma, two lung cancer types that experienced pathologists at times struggle to parse without confirmatory tests. Additionally, the study found that the AI was also able to determine from analyzing the images whether the abnormal versions of six genes linked to lung cancer – including EGFR, KRAS and TP53 – were present in cells, with an accuracy ranging from 73% to 86%, depending upon the gene.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions